867 days. That’s how long it takes, on average, for a new blood cancer drug to move from Health Canada approval to public funding in Canada. LLSC’s new position paper, “Access to innovative blood cancer treatment: Is it fast enough and equitable for all Canadians?” The findings are clear: access is neither fast nor fair. Each province decides when — and if — to fund a treatment and real people pay the price. Joey in B.C. can’t access an MDS treatment that’s publicly funded in every other provinc

Leukemia and Lymphoma Society in Louisville holding Visionaries of the Year campaign

'Yellowstone': Cole Hauser's Son Is Working on Major Charitable Endeavor